Form 6-K Alpha Tau Medical Ltd. For: Oct 19

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2026

 

Commission File Number: 001-41316

 

 

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

CONTENTS

 

On October 19, 2026, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press release dated October 19, 2026.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Alpha Tau Medical Ltd.
Date: October 19, 2026	By:	/s/ Uzi Sofer
		Uzi Sofer
		Chief Executive Officer

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE DATED OCTOBER 19, 2026

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Alpha Tau signs MOU with Samsung Medical Center for pancreatic cancer trial
• VERDA Health Plan of Arizona Forms Partnership with Arizona Priority Care (AZPC) throughout Maricopa And Pima Counties
• Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc. - BBNX